SEC Form SC 13G/A filed by Context Therapeutics Inc. (Amendment)
$CNTX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2025 | $5.00 | Buy | Guggenheim |
| 4/21/2025 | Outperform | William Blair | |
| 1/8/2025 | $4.00 | Mkt Outperform | JMP Securities |
| 11/25/2024 | $9.00 | Buy | D. Boral Capital |
| 5/16/2024 | $4.50 | Overweight | Piper Sandler |
| 2/2/2022 | $6.00 | Buy | HC Wainwright & Co. |
| 1/24/2022 | $10.00 | Buy | ThinkEquity |
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
4 - Context Therapeutics Inc. (0001842952) (Issuer)
SCHEDULE 13G - Context Therapeutics Inc. (0001842952) (Subject)
8-K - Context Therapeutics Inc. (0001842952) (Filer)
SCHEDULE 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
Guggenheim initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $5.00
William Blair initiated coverage of Context Therapeutics with a rating of Outperform
JMP Securities initiated coverage of Context Therapeutics with a rating of Mkt Outperform and set a new price target of $4.00
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences. Upcoming Investor Conferences Guggenheim Emerging Outlook: Biotech Summit 2026, February 11-12, 2026, New York, NYFireside Chat: Wednesday, February 11th at 8:30 AM ET1x1 Meetings on February 11th TD Cowen 46th Annual Health Care Conference, March 2-4, 2026, Boston, MAPresentation: Tuesday, March 3rd at 10:30 AM ET*1x1 Meetings on March 3rd Citizens Life Sciences Conference, March 10-11,
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context. The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted to the new employees on their hire dates (J
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology breakthroughs[1]. This momentum is already materializing, with five major oncology approvals secured in November across multiple cancer indications, demonstrating regulators' willingness to green-light promising therapies when supported by compelling clinical data[2]. Against this backdrop of regulatory evolution, several clinical-stage biotechs are advancing toward definitive registration studies and commercial readiness, po
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights. "We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 ("CLDN6") x CD3 bispecific an
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We continue to advance our clinical pipeline and are pleased to have two product c
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, "We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a s
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product' strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma's recently announced €38 million Series C financing Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, PhD, MBA, LLM a
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer ("CMO"), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company's Board of Directors ("Board"). Dr. Chagin brings over a decade of leadership in clinical development and regulatory strategy for T cell therapies in solid tumors at Adaptimmune Therapeutics plc ("Adaptimmune") and Tmunity
Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025. "I am honored to become the next Chairman of the Board of Directors of Context, where I expect to leverage my experience advising and building fully int
SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)
SC 13G - Context Therapeutics Inc. (0001842952) (Subject)
SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)